Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1988 1
1998 1
1999 1
2002 2
2006 1
2007 2
2009 1
2012 1
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation.
Killinger DW, Perel E, Daniilescu D, Kharlip L, Blackstein ME. Killinger DW, et al. Steroids. 1987 Oct-Dec;50(4-6):523-36. doi: 10.1016/0039-128x(87)90036-5. Steroids. 1987. PMID: 3332939 Review.
Using cultured breast carcinoma cells, it was shown that estrogen formation was stimulated by cortisol (10(-6) M) and inhibited by endogenous 5 alpha-reduced androgens: 5 alpha-androstene-dione greater than androsterone greater than dihydrotestosterone greater than epiandr …
Using cultured breast carcinoma cells, it was shown that estrogen formation was stimulated by cortisol (10(-6) M) and inhibited by en …
Topotecan and cyclophosphamide in adults with relapsed sarcoma.
Blanchette P, Hogg D, Ferguson P, Wunder JS, Swallow C, Gladdy R, Chung P, O'Sullivan B, Blackstein ME, Catton C, Gupta AA. Blanchette P, et al. Sarcoma. 2012;2012:749067. doi: 10.1155/2012/749067. Epub 2012 Jul 18. Sarcoma. 2012. PMID: 22851904 Free PMC article.
Adults treated with TC from 2005 to 2010 were reviewed who received T = topotecan at 0.75 mg/m(2)/day (days 1-5) and C = cyclophosphamide at 250 mg/m(2)/day (days 1-5) every 21 days. ...
Adults treated with TC from 2005 to 2010 were reviewed who received T = topotecan at 0.75 mg/m(2)/day (days 1-5) and C = cyclophospha …
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D, Shepherd L. Findlay B, et al. Ann Oncol. 2007 Oct;18(10):1646-51. doi: 10.1093/annonc/mdm277. Epub 2007 Aug 22. Ann Oncol. 2007. PMID: 17716984 Free article. Clinical Trial.
Cyclophosphamide (C) was given at 700 mg/m(2), 900 mg/m(2), and 1100 mg/m(2) doses. Patients were evaluated for dose-limiting toxicities (DLTs) in the first four cycles, the primary endpoint of the trial. RESULTS: No DLTs were seen at C 700 mg/m(2); at …
Cyclophosphamide (C) was given at 700 mg/m(2), 900 mg/m(2), and 1100 mg/m(2) doses. Patients were evaluated for dose-li …
Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor.
Angarita FA, Hassan S, Cannell AJ, Dickson BC, Gladdy RA, Swallow CJ, Gupta A, Blackstein ME, McCart JA. Angarita FA, et al. Eur J Surg Oncol. 2017 Feb;43(2):423-431. doi: 10.1016/j.ejso.2016.08.017. Epub 2016 Oct 4. Eur J Surg Oncol. 2017. PMID: 27890349
Patients underwent chemotherapy (n = 20), radiation therapy (n = 3), and cytoreductive surgery (CRS) (n = 5). Median OS was 22 m (interquartile range: 12-28 m). Five-year OS rate was 20%. Extra-abdominal metastasis was associated with a higher hazard ratio (HR) of m …
Patients underwent chemotherapy (n = 20), radiation therapy (n = 3), and cytoreductive surgery (CRS) (n = 5). Median OS was 22 m (int …
Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Angarita FA, Cannell AJ, Abdul Razak AR, Dickson BC, Blackstein ME. Angarita FA, et al. BMC Cancer. 2016 Jan 19;16:30. doi: 10.1186/s12885-016-2054-2. BMC Cancer. 2016. PMID: 26786213 Free PMC article.
Partial response or stable disease occurred in 14.1 and 33.8%, respectively, while 52.1% developed progressive disease. Median progression-free survival was 1.3 m (IQR: 0.7-3.5 m) and was significantly higher in patients lacking severe toxicities or progressive dise …
Partial response or stable disease occurred in 14.1 and 33.8%, respectively, while 52.1% developed progressive disease. Median progression-f …
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD. Bramwell VH, et al. Clin Cancer Res. 2002 Feb;8(2):383-93. Clin Cancer Res. 2002. PMID: 11839653 Clinical Trial.
(CIV) infusion of VX-710 (120 mg/m(2)/h) to cohorts of patients to establish a maximum tolerated dose. ...Myelosuppression was the dose-limiting toxicity with 75 and then 67.5 mg/m(2) doxorubicin, and the maximum tolerated dose was established at 60 mg/m(2) w …
(CIV) infusion of VX-710 (120 mg/m(2)/h) to cohorts of patients to establish a maximum tolerated dose. ...Myelosuppression was the do …
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Blackstein M, et al. Oncology. 2002;62(1):2-8. doi: 10.1159/000048240. Oncology. 2002. PMID: 11810037 Clinical Trial.
Prior chemotherapy for metastatic disease was not permitted. Patients received gemcitabine 1,200 mg/m(2) on days 1, 8 and 15 for 3 weeks every 28 days for a maximum of 8 cycles. ...
Prior chemotherapy for metastatic disease was not permitted. Patients received gemcitabine 1,200 mg/m(2) on days 1, 8 and 15 for 3 we …
The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
Perel E, Stolee KH, Kharlip L, Blackstein ME, Killinger DW. Perel E, et al. J Clin Endocrinol Metab. 1984 Mar;58(3):467-72. doi: 10.1210/jcem-58-3-467. J Clin Endocrinol Metab. 1984. PMID: 6693545
After 24-h preincubation with AND, DHT, or 5 alpha-A-dione at concentrations of 10(-6), 10(-7), and 10(-8) M, [3H]androstenedione was added to the culture medium, and aliquots were removed at 0, 4, 8, and 24 h. ...At 10(-7) M, inhibition ranged from 45% (AND) to 70% …
After 24-h preincubation with AND, DHT, or 5 alpha-A-dione at concentrations of 10(-6), 10(-7), and 10(-8) M, [3H]androstenedione was …
Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
Perel E, Daniilescu D, Kharlip L, Blackstein M, Killinger DW. Perel E, et al. J Steroid Biochem. 1988 Apr;29(4):393-9. doi: 10.1016/0022-4731(88)90248-8. J Steroid Biochem. 1988. PMID: 3374128
Progesterone (10(-6) M) had no effect on aromatase activity while the progestational agent R5020 (10(-6) M) produced a 30% inhibition. ...Under the same conditions, the known inhibitor of aromatase, 4-hydroxyandrostenedione (10(-6) M) decreased E1 formation b …
Progesterone (10(-6) M) had no effect on aromatase activity while the progestational agent R5020 (10(-6) M) produced a 30% inh …
14 results